Chagas Disease is an intestinal worm infection caused by the T. cruiselius fungus. Chagas is a very common disease that is most often transmitted via unguarded shared food or water containers. Most cases occur in poor communities that lack basic health services, preventing the disease from being promptly detected and treated. Chagas infection is associated with numerous complications ranging from mild to severe. Common complications associated with Chagas infection are diarrhea, dehydration, shock, kidney failure, heart muscle weakening and death. Some cases of Chagas may be fatal and even lead to necrosis of the affected organs. In cases of Chagas with no identified medical cause, the primary means of treatment is prevention through proper hygiene. The recent past year has witnessed spread of Chagas disease to developed economies such as Europe and North America, due to migration of people from Latin America to others countries. For example, according a study published in National Center for Biotechnology Information (NCBI), in 2015, 4.2% of Latin American living in European countries were chronically affected with Chagas disease. Benznidazole is the only FDA approved treatment indicated for the treatment of Chagas disease. However, the drug, Nifurtimox manufactured by Bayer AG, is in the World Health Organization’s (WHO) list of ‘Essential Medicines’ and used in the treatment of Chagas disease.
Get Sample Report with Latest Covid19 Impact Analysis @ https://www.coherentmarketinsights.com/insight/request-sample/934
Advent of new drug for Chagas disease treatment is expected to drive growth of the global Chagas disease treatment market
Benznidazole is an important antiparasitic drug widely used for the treatment of Chagas disease. For instance, in April 2018, Argentinian National Administration for Drugs, Food, and Medical Technologies (ANMAT) approved Laboratorio Elea Phoenix SA’s drug benznidazole for pediatric indication used for the treatment of Chagas disease. Currently, Argentina has the highest number of people suffering from Chagas disease. For instance, according to data published by Mundo Sano (Nongovernmental foundation in Argentina), in 2017, around 7,300,000 people were exposed to Chagas disease and about 1,600,000 were infected, in Argentina. Hence, increasing approval of novel drugs is projected to augment the market growth in the near future. Such approval of Chagas disease treatment drugs is projected to boost growth of Chagas disease treatment market in the near future.
The global Chagas treatment disease market was valued at US$ 5.67 Mn in 2016 and is expected to witness a CAGR of 7.3% over the forecast period (2017–2025).
Increasing initiatives by private and government organizations for creating awareness of Chagas disease
In April 2018, Médecins Sans Frontières/Doctors Without Borders (MSF), an international humanitarian organization, launched a campaign. The campaign is aimed at increasing public awareness about Chagas disease as the disease is still prevalent in Latin American countries, and affects about 6 million people, globally. In 2007, the World Health Organization (WHO) launched a program to increase treatment rate and eliminate Chagas disease. This WHO program was supported by Bayer HealthCare, which manufactures nifurtimox, used in the treatment of Chagas disease. In 2007, Bayer entered into agreement with WHO to support the program by providing 2.5 million tablets free of charge to WHO, for the treatment of an estimated 30,000 patients over a period of five years (from 2007 to 2011). In 2011, WHO and Bayer extended its agreement. According to the agreement, Bayer is expected to provide 5 million tablets, free of charge, from 2012 to 2017. Such initiatives is expected to drive growth of market in the near future
Get PDF Brochure with Latest Insights @ https://www.coherentmarketinsights.com/insight/request-pdf/934
The Diagnosis of Chagas Disease is done mainly through blood tests and microscopic examination of body fluids. This disease is caused by parasites which live in feces and can be transmitted to other parts of the body by means of blood, secretions and bite marks. The first step in Chagas diagnosis is the obtaining of fresh blood samples in order to obtain serum samples. Serum samples are then sent to a laboratory for testing. It is majorly done by serological methods, parasitological methods, and molecular method. Parasitological methods includes identification of trypomastigotes in blood by microscopy. Polymerase chain reaction (PCR) is a widely used molecular diagnosis method, as it is an ideal alternative tool for detection and shows high range of efficiency. Serological method is mostly used in the detection of Trypanosoma cruzi antibodies in blood donors, diagnosis of infected people and for epidemic studies. Enzyme-linked Immunosorbent Assay (ELISA), Indirect Immunofluorescence (IIF) are the widely used tests in serological method. The availability of rapid diagnostic test and point of care methods has made diagnosis of the disease more simple and quick. In 2016, InBios International, Inc. received 510K clearance from the U.S. Food and Drug Administration (FDA) for its Chagas Detect Plus Rapid Test Kit (CDP).
Key players engaged in the Chagas disease treatment market include Nortec Quimica SA, Bayer AG, Laboratorio Elea Phoenix SA, Maprimed S.A., and Laboratório Farmacêutico de Pernambuco S/A.
Purchase This Premium Report To Access Full Information @ https://www.coherentmarketinsights.com/insight/buy-now/934
Table of Content
Global Chagas Disease Treatment Market Research Report
Section 1: Global Chagas Disease Treatment Industry Overview
Section 2: Global Economic Impact on Chagas Disease Treatment Industry
Section 3: Global Market Competition by Industry Producers
Section 4: Global Productions, Revenue (Value), according to Regions
Section 5: Global Supplies (Production), Consumption, Export, Import, geographically
Section 6: Global Productions, Revenue (Value), Price Trend, Product Type
Section 7: Global Market Analysis, on the basis of Application
Section 8: Chagas Disease Treatment Market Pricing Analysis
Section 9: Market Chain, Sourcing Strategy and Downstream Buyers
Section 10: Strategies and key policies by Distributors/Suppliers/Traders
Section 11: Key Marketing Strategy Analysis, by Market Vendors
Section 12: Market Effect Factors Analysis
Section 13: Global Chagas Disease Treatment Market Forecast
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027